Hospital
Huggins Hospital
Huggins Hospital was paid $5.36M by Medicaid between Jan 2018 and Nov 2024, across 105 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoHUGGINS HOSPITAL
WOLFEBORO, NH 03894
WOLFEBORO, NH 03894
33aNPI1366476079assigned 07/10/2006
33bProvider typeCritical Access Hospital
28Total paid$5.36M
24GClaims132,531
24DCodes billed105
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in New Hampshire
Rank by total paid#4 of 9
Median peer was paid$5.24M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,986 | $464K | |
| 2019 | 24,534 | $788K | |
| 2020 | 24,004 | $1.05M | |
| 2021 | 33,766 | $1.56M | |
| 2022 | 22,927 | $1.26M | |
| 2023 | 5,205 | $163K | |
| 2024incomplete | 3,109 | $82K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 6,399 | 5,250 | $1.27M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 3,299 | 2,400 | $805K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.6% | 1,748 | 1,306 | $406K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.0% | 5,268 | 1,529 | $378K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.3% | 282 | 226 | $340K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.8% | 2,135 | 854 | $203K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 3.6% | 3,266 | 1,028 | $192K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.1% | 3,494 | 2,431 | $166K |
| 71046 | Radiologic examination, chest; 2 views | 2.9% | 1,490 | 1,172 | $154K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 303 | 218 | $134K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.1% | 1,038 | 676 | $112K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.0% | 10,435 | 3,910 | $105K |
93 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 1,515 | $97K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.6% | 928 | $85K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 1,096 | $67K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 1,014 | $66K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.2% | 441 | $65K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.2% | 3,576 | $63K |
| 80053 | Comprehensive metabolic panel | 1.0% | 11,695 | $55K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,223 | $52K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,100 | $40K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 529 | $39K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 6,032 | $37K |
| 97161 | <1% | 464 | $34K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,062 | $34K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 887 | $30K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 324 | $28K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,430 | $26K |
| 80061 | Lipid panel | <1% | 3,108 | $25K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,405 | $22K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 15 | $17K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 42 | $12K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,036 | $11K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,998 | $11K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 488 | $9K |
| 80306 | <1% | 891 | $8K | |
| 81001 | <1% | 4,734 | $8K | |
| 84484 | <1% | 2,321 | $8K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 41 | $7K |
| 96376 | <1% | 127 | $7K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,984 | $7K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 224 | $6K |
| 83735 | <1% | 2,095 | $6K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 361 | $6K |
| G0378 | Hospital observation service, per hour | <1% | 16 | $5K |
| 85027 | <1% | 1,433 | $5K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 146 | $5K |
| 80050 | General health panel | <1% | 519 | $4K |
| 73130 | <1% | 24 | $4K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 189 | $4K |
| 72100 | <1% | 19 | $4K | |
| 87088 | <1% | 1,695 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,568 | $3K |
| 83690 | <1% | 886 | $3K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 86 | $3K |
| 84703 | <1% | 616 | $3K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 15 | $3K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 42 | $3K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 76 | $3K |
| 73562 | <1% | 22 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 296 | $3K |
| 86140 | <1% | 900 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 874 | $2K |
| 82077 | <1% | 229 | $2K | |
| 83880 | <1% | 233 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 111 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 111 | $2K |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 652 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 49 | $2K |
| 74018 | <1% | 16 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 461 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 650 | $2K |
| 73110 | <1% | 17 | $2K | |
| 87077 | <1% | 440 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 36 | $2K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 29 | $2K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 51 | $2K |
| 85610 | <1% | 1,199 | $2K | |
| 83605 | <1% | 428 | $1K | |
| 87081 | <1% | 311 | $1K | |
| 87186 | <1% | 302 | $1K | |
| 88142 | <1% | 81 | $1K | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 675 | $1K |
| 82607 | <1% | 200 | $1K | |
| 87040 | <1% | 242 | $1K | |
| 85651 | <1% | 370 | $936.03 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 18 | $797.36 |
| 86618 | <1% | 106 | $676.51 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 19 | $580.38 |
| G0008 | Administration of influenza virus vaccine | <1% | 486 | $569.76 |
| 90686 | <1% | 364 | $387.37 | |
| 84439 | <1% | 71 | $378.01 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 61 | $350.43 |
| 82947 | <1% | 225 | $322.43 | |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | <1% | 25 | $315.00 |
| 82728 | <1% | 37 | $300.95 | |
| 83540 | <1% | 60 | $273.40 | |
| 87806 | <1% | 16 | $257.04 | |
| 85379 | <1% | 41 | $225.30 | |
| 99307 | <1% | 55 | $223.90 | |
| 82746 | <1% | 19 | $201.56 | |
| 85730 | <1% | 70 | $174.84 | |
| 83550 | <1% | 13 | $150.08 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 37 | $108.46 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 150 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROBERGE, JEREMY (PRESIDENT & CEO)
| Provider | Location | Paid |
|---|---|---|
| Huggins Hospital | Wolfeboro, NH | $551K |
| Huggins Hospital | Tamworth, NH | $159K |
| Huggins Hospital | Alton, NH | $118K |
| Huggins Hospital | Wolfeboro, NH | $106K |
| Huggins Hospital | Ossipee, NH | $67K |
| Huggins Hospital | Moultonborough, NH | $14K |
| Huggins Hospital | Wolfeboro, NH | $2K |
| Huggins Hospital | Wolfeboro, NH | $2K |
| Huggins Hospital | Wolfeboro, NH | $567.63 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.